Efficient Maternofetal Transplacental Transfer of Anti- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Antibodies After Antenatal SARS-CoV-2 BNT162b2 Messenger RNA Vaccination

Amihai Rottenstreich; Gila Zarbiv; Esther Oiknine-Djian; Roy Zigron; Dana G Wolf; Shay Porat

doi:10.1093/cid/ciab266

Efficient Maternofetal Transplacental Transfer of Anti- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Antibodies After Antenatal SARS-CoV-2 BNT162b2 Messenger RNA Vaccination

Clin Infect Dis. 2021 Nov 16;73(10):1909-1912. doi: 10.1093/cid/ciab266.

Authors

Amihai Rottenstreich¹, Gila Zarbiv¹, Esther Oiknine-Djian², Roy Zigron¹, Dana G Wolf², Shay Porat¹

Affiliations

¹ Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
² Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Abstract

Maternal and cord blood sera were collected from 20 parturients who received the BNT162b2 vaccine. All women and infants were positive for anti S- and anti-receptor binding domain antibody-specific immunoglobulin G. Cord blood antibody concentrations were correlated to maternal levels and to time since vaccination. Antenatal severe acute respiratory syndrome coronavirus 2 vaccination may provide maternal and neonatal protection.

Keywords: SARS-CoV-2; cord blood; pregnancy; serology; vaccination.

MeSH terms

Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Female
Humans
Infant, Newborn
Pregnancy
RNA, Messenger
SARS-CoV-2*
Vaccination

Substances

Antibodies, Viral
COVID-19 Vaccines
RNA, Messenger
BNT162 Vaccine